HomeCompareXLNX vs JNJ

XLNX vs JNJ: Dividend Comparison 2026

XLNX yields 8.04% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $1.7K in total portfolio value· pulled ahead in Year 10
10 years
XLNX
XLNX
● Live price
8.04%
Share price
$194.92
Annual div
$15.68
5Y div CAGR
-8.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.6K
Annual income
$493.88
Full XLNX calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — XLNX vs JNJ

📍 JNJ pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXLNXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XLNX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XLNX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XLNX
Annual income on $10K today (after 15% tax)
$683.77/yr
After 10yr DRIP, annual income (after tax)
$419.80/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,566.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XLNX + JNJ for your $10,000?

XLNX: 50%JNJ: 50%
100% JNJ50/50100% XLNX
Portfolio after 10yr
$29.4K
Annual income
$2,591.64/yr
Blended yield
8.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

XLNX
Analyst Ratings
16
Buy
28
Hold
1
Sell
Consensus: Hold
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XLNX buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXLNXJNJ
Forward yield8.04%2.13%
Annual dividend / share$15.68$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-8.1%28%
Portfolio after 10y$28.6K$30.3K
Annual income after 10y$493.88$4,689.40
Total dividends collected$6.3K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: XLNX vs JNJ ($10,000, DRIP)

YearXLNX PortfolioXLNX Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,439$739.27$10,592$272.30+$847.00XLNX
2$12,966$726.33$11,289$357.73+$1.7KXLNX
3$14,581$707.11$12,123$472.89+$2.5KXLNX
4$16,285$682.95$13,141$629.86+$3.1KXLNX
5$18,080$655.11$14,408$846.81+$3.7KXLNX
6$19,970$624.68$16,021$1,151.60+$3.9KXLNX
7$21,961$592.62$18,122$1,588.22+$3.8KXLNX
8$24,058$559.72$20,930$2,228.20+$3.1KXLNX
9$26,268$526.64$24,792$3,191.91+$1.5KXLNX
10← crossover$28,601$493.88$30,274$4,689.40$1.7KJNJ

XLNX vs JNJ: Complete Analysis 2026

XLNXStock

Xilinx, Inc. designs, develops, and markets programmable devices and associated technologies worldwide. The company offers integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; adaptive compute acceleration platform; software design tools to program the PLDs; software development environments and embedded platforms; targeted reference designs; printed circuit boards; and intellectual property (IP) core licenses covering Ethernet, memory controllers, Interlaken, and peripheral component interconnect express interfaces, as well as domain-specific IP in the areas of embedded, digital signal processing and connectivity, and market-specific IP cores. It also offers development boards; development kits, including hardware, design tools, IP, and reference designs that are designed to streamline and accelerate the development of domain-specific and market-specific applications; and configuration products comprising one-time programmable and in-system programmable storage devices to configure field programmable gate arrays. In addition, it provides design, customer training, field engineering, and technical support services. The company offers its products to electronic equipment manufacturers in sub- markets, such as data center, wireless, wired, aerospace and defense, test, measurement and emulation, industrial, scientific and medical, automotive, audio, video and broadcast, and consumer. It sells its products through a network of independent distributors; and through direct sales to original equipment manufacturers and electronic manufacturing service providers, as well as independent sales representatives. Xilinx, Inc. was incorporated in 1984 and is headquartered in San Jose, California. As of February 14, 2022, Xilinx, Inc. operates as a subsidiary of Advanced Micro Devices, Inc.

Full XLNX Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this XLNX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XLNX vs SCHDXLNX vs JEPIXLNX vs OXLNX vs KOXLNX vs MAINXLNX vs ABBVXLNX vs MRKXLNX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.